Experimental model of reversible myelosuppression caused by short-term, high-dose oxazolidinone administration

Therapy

Volumn 3, Issue 4, 2006, Pages 521-526

  Hickey, Emily J ^a   Gill, C J ^a   Misura, A S ^a   Flattery, A F ^a   Abruzzo, G K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Animal models; Infectious diseases; Linezolid; Myelosuppression; Therapy

Indexed keywords

CHLORAMPHENICOL; LINEZOLID; OXAZOLIDINONE DERIVATIVE;

ANEMIA; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CONTROLLED STUDY; CYTOPENIA; DISEASE MODEL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; MOUSE; NONHUMAN; RETICULOCYTOSIS; STRUCTURE ACTIVITY RELATION;

EID: 33748869043     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.1586/14750708.3.4.521     Document Type: Article

References (22)

1. Chen JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multi-drug resistant Gram-positive bacterial infections. Clin. Infect. Dis. 30, 146-151 (2000).
2. Noskin GA, Siddiqui F. Storsor V. Hacek D, Peterson LR. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin resistant enterococci. Antimicrob. Agents Chemother. 43, 2059-2062 (1999).
3. Andes D, Van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamic activity of a new oxazolidinone (Linezolid). Antimicrob. Agents Chemother. 46, 3484-3489 (2002).
4. Zurenko GE, Yagi BH, Schaadt RD et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40, 839-845 (1996).
5. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother. 42, 3251-3255 (1998).
6. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18, 456-462 (1998).
7. Hau T. Efficacy and safety of linezolid In the treatment of skin and soft tissue infections. Euro. J. Clin. Microbiol. Infect. Dis. 21, 491-498 (2002).
8. Hartman CS, Leach TS, Kaja RW, Schaser RJ, Todd WM. Linezolid in the treatment of vancomycin-resistant enterococcus: a dose comparative, multicenter Phase III trial. In: Program and Abstracts of the Fortieth Interscience Conference on Antimicrob. Agents Chemother. Toronto, Ontario, Canada, 2000. Abstract 2235, p. 488. American Society for Microbiology, Washington, DC, USA (2000).
9. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 34, 1481-1490 (2002).
10. Rubinstein E, Cammarata SK, Oliphant TH. Wunderink RG & the Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 32, 402-412 (2001).
11. FOI- linezolid, Pharmacia.
12. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. J. Amer. Med. Ass. 285. 1291-1293 (2001).
13. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. 34. 695 (2002).
14. Birmingham MC, Rayner CR, Meagher AK et al. Linezolid for the treatment of multidrug resistant, Gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36, 159-168 (2003).
15. Smith PF, Birmingham MC, Noskin GA et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Grampositive infections in cancer patients with neutropenia. Ann. Oncol. 14, 795-801 (2003).
16. Hachem RY, Hicks K, Huenh A, Raad I. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin. Infect. Dis. 37. E8-E11 (2003).
17. Rubenstein E, Isturiz R, Standiford HC et al. Worldwide assessment of linezolid's clinical safety and tolerability: Comparator-controlled Phase III studies. Antimicrob. Agents Chemother. 47 (6): 1824-1831 (2003).
18. French G. Safety and tolerability of linezolid. J. Antimicrob. Chemother. 51, (Suppl. 52), S45-S53 (2003).
19. Rao N. Ziran BH, Wagener MW et al. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin. Infect. Dis. 38, 1058-1064 (2004).
20. Festing MF, Diamanti P, Turton JA. Strain differences in hematological response to chloramphenicol succinate in mice: implications for toxicological research. Food Chem. Toxicol. 39(4), 375-383 (2001).
21. Best WR. Chloramphenicol associated blood dyscrasias. J. Am. Med. Ass. 201, 99-106 (1967).
22. Holt D, Harvey G, Hurley R. Chloramphenicol toxicity. Adv. Drug React. Toxicol. Rev. 12, 83-95 (1993).